<DOC>
	<DOCNO>NCT02758769</DOCNO>
	<brief_summary>Examine effectiveness safety abatacept administration biologic-naïve rheumatoid arthritis patient moderate disease activity despite treatment conventional synthetic disease modify anti-rheumatic drug .</brief_summary>
	<brief_title>Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients RA meet 2010 American College Rheumatology / European League Rheumatisms ( ACR/EULAR ) RA Classification Criteria Patients RA moderate disease activity ( SDAI : &gt; 11 26 ) Biologicnaive patient treatment history csDMARDs Patients meet follow criterion hematological examination : Peripheral white blood cell count : 4,000/mm3 Peripheral lymphocyte count : 1,000/mm3 Blood βDglucan negative Patients understand investigator 's explanation study procedure give voluntary write consent participate study Patients initiate abatacept per physician 's therapeutic decision Past history hypersensitivity component abatacept preparation Disease complication comorbidity Active infectious disease Been judge investigator coinvestigator inappropriate Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>